医学
耐受性
头皮
米诺地尔
皮肤病科
安慰剂
随机对照试验
绒毛
外科
内科学
不利影响
病理
替代医学
作者
Varvara Kanti,Kathrin Hillmann,Jan Kottner,Andrea Stroux,Douglas Canfield,Ulrike Blume‐Peytavi
摘要
Abstract Background Topical minoxidil formulations have been shown to be effective in treating androgenetic alopecia ( AGA ) for 12 months. Efficacy and safety in both frontotemporal and vertex regions over longer application periods have not been studied so far. Objectives To evaluate the effect of 5% minoxidil topical foam (5% MTF ) in the frontotemporal and vertex areas in patients with moderate AGA over 104 weeks. Methods An 80‐week, open‐label extension phase was performed, following a 24‐week randomized, double‐blind, placebo‐controlled study in men with AGA grade III vertex to VI . Group 1 ( n = 22) received ongoing 5% MTF for 104 weeks, Group 2 ( n = 23) received placebo topical foam (pla TF ) until week 24, followed by 5% MTF until week 104 during the extension phase. Frontotemporal and vertex target area non‐vellus hair counts (f‐ TAHC , v‐ TAHC ) and cumulative hair width (f‐ TAHW , v‐ TAHW ) were assessed at baseline and at weeks 24, 52, 76 and 104. Results In Group 1, f‐ TAHW and f‐ TAHC showed a statistically significant increase from baseline to week 52 and week 76, respectively, returning to values comparable to baseline at week 104. No significant differences were found between baseline and week 104 in v‐ TAHC in Group 1 as well as f‐ TAHC , v‐ TAHC , f‐ TAHW and v‐ TAHW values in Group 2. Conclusions 5% MTF is effective in stabilizing hair density, hair width and scalp coverage in both frontotemporal and vertex areas over an application period of 104 weeks, while showing a good safety and tolerability profile with a low rate of irritant contact dermatitis.
科研通智能强力驱动
Strongly Powered by AbleSci AI